NASDAQ Flops, Dow Jumps
The S&P 500 and NASDAQ were down sharply Monday on concern about an artificial intelligence stock bubble popping because of the emergence of Chinese startup DeepSeek, which has possibly made a competitive AI model for a fraction of the billions Silicon Valley is spending.The Dow Jones Industrials popped 289.33 points to close Monday at 44,713.58, thanks to gains in Apple, Johnson & Johnson and Travelers.The much-broader index flopped 88.96 points, or 1.5%, to 6,012.28. The NASDAQ Composite swooned 612.47 points, or 3.1%, to 19,341.83. AI darling Nvidia dropped 18%, Broadcom lost 17%, and AMD shed 7%. Microsoft lost 2%. Palantir was hit for 6%. Megacap tech titan Amazon shed 1%.Derivative plays from the AI buildout such as power providers were also hit big. Constellation Energy lost 21%, while Vistra dropped 30%.On top of that, the Federal Reserve will hold its first policy meeting of the year, deciding on the level of interest rates Wednesday. Fed funds futures are pricing in a more than 99% chance that the central bank leaves interest rates unchanged. Prices for the 10-year Treasury gained ground, lowering yields to 4.53% from Friday’s 4.62%. Treasury prices and yields move in opposite directions.Oil prices dropped $1.60 to $73.08 U.S. a barrel. Prices for gold plunged $36.00 an ounce to $2,742.90.80 U.S. NASDAQ Flops, Dow Jumps
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


